Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49,883,741
-
Total 13F shares
-
679,602
-
Share change
-
+505,011
-
Total reported value
-
$5,741,892
-
Price per share
-
$8.45
-
Number of holders
-
19
-
Value change
-
+$4,267,930
-
Number of buys
-
12
-
Number of sells
-
2
Institutional Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q4 2023
As of 31 Dec 2023,
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
679,602 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, HC Advisors, LLC, Connecticut Wealth Management, LLC, HRT FINANCIAL LP, Anson Capital, Inc., WETHERBY ASSET MANAGEMENT INC, Tyche Wealth Partners LLC, NORTHERN TRUST CORP, and UBS Group AG.
This page lists
19
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.